Table 1. Demographic and clinical parameters of study participants.
| SLE patients | Healthy controls | |||
|---|---|---|---|---|
| 0 week | 4 weeks | 12 weeks | ||
| Number of patients | n = 22 | n = 16 | n = 17 | n = 14 |
| Age in years | 39 (23–58) | 41 (24–57) | ||
| SLEDAI | 14 (6–23) | 6(1–18)* | 3(0–8)* | - |
| Positive Anti-dsDNA | 17 (77.3%) | 8 (50%)* | 5 (29.4%)* | - |
| Positive Anti-Sm | 6 (27.7%) | 5 (31.25%) | 2 (11.76%) | - |
| C3 (mg/L) | 0.50 (0.05–1.16) | 0.98 (0.59–1.25)* | 1.17 (0.73–1.56)* | - |
| C4 (mg/L) | 0.10 (0.01–0.49) | 0.14 (0.05–0.25)* | 0.18 (0.06–0.34)* | - |
| CRP (mg/L) | 5.44 (0.86–24.4) | 2.02 (0.16–11.2) | 3.41 (0.16–9.31) | - |
| ESR(mm/H) | 52.4(3–111) | 18.5(3–91) | 24(4–61) | - |
| WBC (x109/L) | 3.66 (0.65–7.05) | 9.46 (3.42–15.4)* | 9.81 (3.14–18.93)* | 6.80 (4.44–10.3)* |
| PLT(x109/L) | 132 (26–293) | 189 (95–315)* | 227 (138–353)* | 212 (128–295)* |
| LY (x109/L) | 0.78 (0.31–2.18) | 1.69 (0.7–2.71)* | 2.59 (1.1–6.75)* | 2.1 (1.49–3.51)* |
Data shown are median (range) for each group of subjects, except for those specified otherwise. SLEDAI: systemic lupus erythematosus (SLE) disease activity index; CRP: C-reactive protein; C3 and C4: complements 3 and 4; WBC: white blood cells; PLT: blood platelet; LY: lymphocytes; 0 week: baseline or before therapy; 4 weeks and 12 weeks: 4 and 12 weeks after therapies
*: P<0.05 vs. baseline values.
(–) indicates levels undetected.